Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Equity-to-Asset 0.45
ABT's Equity-to-Asset is ranked lower than
82% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ABT: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
ABT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.47 Max: 0.59
Current: 0.45
0.37
0.59
Debt-to-Equity 0.68
ABT's Debt-to-Equity is ranked lower than
87% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. ABT: 0.68 )
Ranked among companies with meaningful Debt-to-Equity only.
ABT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16  Med: 0.47 Max: 1.07
Current: 0.68
0.16
1.07
Debt-to-EBITDA 3.16
ABT's Debt-to-EBITDA is ranked lower than
77% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. ABT: 3.16 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ABT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.39  Med: 2 Max: 7.11
Current: 3.16
1.39
7.11
Interest Coverage 3.68
ABT's Interest Coverage is ranked lower than
95% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 66.37 vs. ABT: 3.68 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s Interest Coverage Range Over the Past 10 Years
Min: 1.91  Med: 10.99 Max: 17.59
Current: 3.68
1.91
17.59
Piotroski F-Score: 5
Altman Z-Score: 3.07
Beneish M-Score: -2.72
WACC vs ROIC
10.93%
2.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 10.45
ABT's Operating Margin % is ranked higher than
60% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ABT: 10.45 )
Ranked among companies with meaningful Operating Margin % only.
ABT' s Operating Margin % Range Over the Past 10 Years
Min: 6.3  Med: 13.45 Max: 20.27
Current: 10.45
6.3
20.27
Net Margin % 2.91
ABT's Net Margin % is ranked higher than
51% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ABT: 2.91 )
Ranked among companies with meaningful Net Margin % only.
ABT' s Net Margin % Range Over the Past 10 Years
Min: 1.74  Med: 14.84 Max: 31.3
Current: 2.91
1.74
31.3
ROE % 2.83
ABT's ROE % is ranked higher than
52% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. ABT: 2.83 )
Ranked among companies with meaningful ROE % only.
ABT' s ROE % Range Over the Past 10 Years
Min: 1.85  Med: 20.2 Max: 28.49
Current: 2.83
1.85
28.49
ROA % 1.23
ABT's ROA % is ranked higher than
53% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. ABT: 1.23 )
Ranked among companies with meaningful ROA % only.
ABT' s ROA % Range Over the Past 10 Years
Min: 0.74  Med: 8.01 Max: 12.12
Current: 1.23
0.74
12.12
ROC (Joel Greenblatt) % 33.61
ABT's ROC (Joel Greenblatt) % is ranked higher than
76% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. ABT: 33.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.81  Med: 30.65 Max: 75.77
Current: 33.61
0.81
75.77
3-Year Revenue Growth Rate 5.70
ABT's 3-Year Revenue Growth Rate is ranked higher than
53% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ABT: 5.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.9  Med: 9.1 Max: 15.2
Current: 5.7
-17.9
15.2
3-Year EBITDA Growth Rate 8.40
ABT's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. ABT: 8.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 10.2 Max: 20.9
Current: 8.4
-34
20.9
3-Year EPS without NRI Growth Rate -43.70
ABT's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 7.80 vs. ABT: -43.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.6  Med: 10.5 Max: 125.5
Current: -43.7
-65.6
125.5
GuruFocus has detected 6 Warning Signs with Abbott Laboratories ABT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABT's 30-Y Financials

Financials (Next Earnings Date: 2019-01-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ABT Guru Trades in Q3 2017

Ray Dalio 7,623 sh (New)
Joel Greenblatt 17,851 sh (New)
Steven Cohen 894,179 sh (New)
Mairs and Power 4,570,254 sh (+0.92%)
Ken Fisher 346,505 sh (+0.90%)
John Buckingham 134,052 sh (+0.42%)
David Carlson 200,000 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Richard Pzena Sold Out
Jim Simons Sold Out
Jeff Auxier 108,165 sh (-0.14%)
Tom Russo 16,500 sh (-0.60%)
PRIMECAP Management 14,705,543 sh (-1.20%)
Mario Gabelli 66,728 sh (-1.34%)
Vanguard Health Care Fund 21,110,694 sh (-1.50%)
Murray Stahl 23,228 sh (-5.09%)
Dodge & Cox 27,332 sh (-6.61%)
Jeremy Grantham 4,853,567 sh (-7.59%)
Diamond Hill Capital 11,039,767 sh (-7.73%)
» More
Q4 2017

ABT Guru Trades in Q4 2017

First Pacific Advisors 7,700 sh (New)
Pioneer Investments 1,164,354 sh (New)
Joel Greenblatt 857,483 sh (+4703.56%)
Steven Cohen 1,788,535 sh (+100.02%)
Steven Cohen 600,000 sh (unchged)
Robert Bruce 230,915 sh (unchged)
David Carlson Sold Out
Ray Dalio Sold Out
John Buckingham 133,996 sh (-0.04%)
Dodge & Cox 27,229 sh (-0.38%)
Mairs and Power 4,543,385 sh (-0.59%)
PRIMECAP Management 14,613,519 sh (-0.63%)
Mario Gabelli 66,283 sh (-0.67%)
Jeremy Grantham 4,820,367 sh (-0.68%)
Murray Stahl 23,028 sh (-0.86%)
Jeff Auxier 104,386 sh (-3.49%)
Diamond Hill Capital 10,559,736 sh (-4.35%)
Vanguard Health Care Fund 19,140,784 sh (-9.33%)
Ken Fisher 311,969 sh (-9.97%)
Tom Russo 12,800 sh (-22.42%)
» More
Q1 2018

ABT Guru Trades in Q1 2018

MS Global Franchise Fund 283,662 sh (New)
Eaton Vance Worldwide Health Sciences Fund 201,406 sh (New)
First Pacific Advisors 20,800 sh (+170.13%)
Ken Fisher 404,157 sh (+29.55%)
Pioneer Investments 1,361,015 sh (+16.89%)
Robert Bruce 246,715 sh (+6.84%)
John Buckingham 135,479 sh (+1.11%)
Tom Russo 12,800 sh (unchged)
Dodge & Cox 27,229 sh (unchged)
Murray Stahl 23,028 sh (unchged)
Jeff Auxier 104,135 sh (-0.24%)
Diamond Hill Capital 10,466,682 sh (-0.88%)
PRIMECAP Management 14,480,510 sh (-0.91%)
Mario Gabelli 64,115 sh (-3.27%)
Mairs and Power 4,257,369 sh (-6.30%)
Vanguard Health Care Fund 16,969,881 sh (-11.34%)
Jeremy Grantham 3,384,241 sh (-29.79%)
Joel Greenblatt 600,639 sh (-29.95%)
Steven Cohen 1,100 sh (-99.94%)
» More
Q2 2018

ABT Guru Trades in Q2 2018

Paul Tudor Jones 5,400 sh (New)
Caxton Associates 18,108 sh (New)
MS Global Franchise Fund 531,566 sh (+87.39%)
Pioneer Investments 1,787,524 sh (+31.34%)
Robert Bruce 286,715 sh (+16.21%)
Tom Russo 13,960 sh (+9.06%)
Ken Fisher 409,453 sh (+1.31%)
Eaton Vance Worldwide Health Sciences Fund 276,884 sh (+37.48%)
Murray Stahl 23,028 sh (unchged)
Dodge & Cox 27,229 sh (unchged)
Steven Cohen Sold Out
PRIMECAP Management 14,411,590 sh (-0.48%)
John Buckingham 133,864 sh (-1.19%)
Jeff Auxier 101,856 sh (-2.19%)
Vanguard Health Care Fund 16,532,781 sh (-2.58%)
Diamond Hill Capital 10,116,925 sh (-3.34%)
Mario Gabelli 60,705 sh (-5.32%)
Mairs and Power 3,845,348 sh (-9.68%)
Jeremy Grantham 2,558,239 sh (-24.41%)
First Pacific Advisors 14,000 sh (-32.69%)
Joel Greenblatt 168,075 sh (-72.02%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 Reduce -2.58%0.06%$57.57 - $63.54 $ 68.2013%16,532,781
Ken Fisher 2018-06-30 Add 1.31%$57.57 - $63.54 $ 68.2013%409,453
Robert Bruce 2018-06-30 Add 16.21%0.53%$57.57 - $63.54 $ 68.2013%286,715
Joel Greenblatt 2018-06-30 Reduce -72.02%0.36%$57.57 - $63.54 $ 68.2013%168,075
Mario Gabelli 2018-06-30 Reduce -5.32%$57.57 - $63.54 $ 68.2013%60,705
Vanguard Health Care Fund 2018-03-31 Reduce -11.34%0.27%$56.27 - $63.62 $ 68.2013%16,969,881
Joel Greenblatt 2018-03-31 Reduce -29.95%0.21%$56.27 - $63.62 $ 68.2013%600,639
Ken Fisher 2018-03-31 Add 29.55%0.01%$56.27 - $63.62 $ 68.2013%404,157
Robert Bruce 2018-03-31 Add 6.84%0.21%$56.27 - $63.62 $ 68.2013%246,715
Mario Gabelli 2018-03-31 Reduce -3.27%$56.27 - $63.62 $ 68.2013%64,115
Vanguard Health Care Fund 2017-12-31 Reduce -9.33%0.23%$53.68 - $57.47 $ 68.2023%19,140,784
Joel Greenblatt 2017-12-31 Add 4703.56%0.7%$53.68 - $57.47 $ 68.2023%857,483
Ken Fisher 2017-12-31 Reduce -9.97%$53.68 - $57.47 $ 68.2023%311,969
Mario Gabelli 2017-12-31 Reduce -0.67%$53.68 - $57.47 $ 68.2023%66,283
Dodge & Cox 2017-12-31 Reduce -0.38%$53.68 - $57.47 $ 68.2023%27,229
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:MDT, NYSE:SYK, NAS:ISRG, NYSE:BSX, NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., NAS:ABMD, NYSE:TFX, XSWX:SOON, NYSE:VAR, SZSE:300003, OCSE:WDH, XPAR:DIM, ASX:COH, LSE:CTEC, NZSE:FPH, NYSE:GMED, OCSE:AMBU B » details
Traded in other countries:ABT.Argentina, ABT.Austria, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, 0Q15.UK,
Headquarter Location:USA
Abbott Laboratories is a health care company that manufactures medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs.

Abbott manufactures and markets medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, coronary stents, catheters, infant formula, nutritional liquids for adults, vessel closure devices, and Lasik equipment. Abbott derives approximately 60% of sales outside the United States.

Guru Investment Theses on Abbott Laboratories

Keeley Funds Comments on Abbott Labs - Aug 14, 2017

Abbott Labs (NYSE:ABT) is a large, multinational health care products company focusing on pharmaceuticals, diagnostic and nutritional products. The company reported a nice quarter beating estimates for both sales and earnings, and continued to execute well on the integration of recently acquired St. Jude Medical. Abbott also cleared the last hurdle to complete the long-delayed purchase of Alere (ALR) which should close in the third quarter of 2017.



From Keeley All Cap Value Fund second quarter 2017 shareholder commentary.



Check out Keeley Asset Management Corp latest stock trades

Top Ranked Articles about Abbott Laboratories

Abbott's HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant
Abbott Labs Declines on 3rd-Quarter Earnings The US health care company matched consensus on earnings
The U.S. health care company Abbott Laboratories (NYSE:ABT) reported strong third-quarter results before the opening bell on Wednesday, though shares declined 1.01% to $70.23. Read more...
New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care
Abbott Names Robert B. Ford President, Chief Operating Officer
Abbott′s FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe
Abbott Labs' Test for Heart Attack Risk Granted With CE Mark The biomarker will also be used in healthy people
On Wednesday Abbott Laboratories (NYSE:ABT) informed the market that its High Sensitive Troponin-I blood test is now certified with a CE marking. Read more...
Abbott Receives CE Mark for First Troponin Test to Help Predict the Chance of Heart Attack in Apparently Healthy Adults Potentially Months to Years in Advance
One-Year Results from Real-World Study Showed Abbott's Portico™ Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis
5 Companies Hit 52-Week Highs Recently, multiple companies have all managed to achieve yearly highs
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-week highs. Read more...
Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation

Ratios

vs
industry
vs
history
PE Ratio 136.96
ABT's PE Ratio is ranked lower than
97% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. ABT: 136.96 )
Ranked among companies with meaningful PE Ratio only.
ABT' s PE Ratio Range Over the Past 10 Years
Min: 5.78  Med: 12.07 Max: 254.4
Current: 136.96
5.78
254.4
Forward PE Ratio 20.79
ABT's Forward PE Ratio is ranked higher than
65% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. ABT: 20.79 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 152.18
ABT's PE Ratio without NRI is ranked lower than
98% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. ABT: 152.18 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.93  Med: 31.78 Max: 333.79
Current: 152.18
5.93
333.79
Price-to-Owner-Earnings 24.66
ABT's Price-to-Owner-Earnings is ranked higher than
62% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 32.03 vs. ABT: 24.66 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.53  Med: 12.71 Max: 761.33
Current: 24.66
4.53
761.33
PB Ratio 3.92
ABT's PB Ratio is ranked lower than
58% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. ABT: 3.92 )
Ranked among companies with meaningful PB Ratio only.
ABT' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 2.38 Max: 4.21
Current: 3.92
1.39
4.21
PS Ratio 4.07
ABT's PS Ratio is ranked lower than
56% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. ABT: 4.07 )
Ranked among companies with meaningful PS Ratio only.
ABT' s PS Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.88 Max: 6.24
Current: 4.07
0.96
6.24
Price-to-Free-Cash-Flow 25.01
ABT's Price-to-Free-Cash-Flow is ranked higher than
55% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. ABT: 25.01 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.39  Med: 11.87 Max: 40.05
Current: 25.01
4.39
40.05
Price-to-Operating-Cash-Flow 20.09
ABT's Price-to-Operating-Cash-Flow is ranked higher than
50% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. ABT: 20.09 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.82  Med: 8.39 Max: 23.85
Current: 20.09
3.82
23.85
EV-to-EBIT 39.81
ABT's EV-to-EBIT is ranked lower than
76% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. ABT: 39.81 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: -214.2  Med: 23.35 Max: 5424.4
Current: 39.81
-214.2
5424.4
EV-to-EBITDA 21.03
ABT's EV-to-EBITDA is ranked lower than
56% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. ABT: 21.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.1  Med: 15.1 Max: 28.4
Current: 21.03
4.1
28.4
EV-to-Revenue 4.52
ABT's EV-to-Revenue is ranked lower than
61% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. ABT: 4.52 )
Ranked among companies with meaningful EV-to-Revenue only.
ABT' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 3 Max: 6.8
Current: 4.52
1.2
6.8
PEG Ratio 16.51
ABT's PEG Ratio is ranked lower than
97% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. ABT: 16.51 )
Ranked among companies with meaningful PEG Ratio only.
ABT' s PEG Ratio Range Over the Past 10 Years
Min: 0.41  Med: 1.03 Max: 140.36
Current: 16.51
0.41
140.36
Shiller PE Ratio 26.84
ABT's Shiller PE Ratio is ranked higher than
81% of the 58 Companies
in the Global Medical Devices industry.

( Industry Median: 49.95 vs. ABT: 26.84 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.03  Med: 13.22 Max: 28.77
Current: 26.84
9.03
28.77
Current Ratio 1.58
ABT's Current Ratio is ranked lower than
58% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. ABT: 1.58 )
Ranked among companies with meaningful Current Ratio only.
ABT' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.36 Max: 4.02
Current: 1.58
0.75
4.02
Quick Ratio 1.16
ABT's Quick Ratio is ranked lower than
53% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ABT: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.01 Max: 3.65
Current: 1.16
0.55
3.65
Days Inventory 104.13
ABT's Days Inventory is ranked higher than
67% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. ABT: 104.13 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 80.31  Med: 103.72 Max: 145.14
Current: 104.13
80.31
145.14
Days Sales Outstanding 62.33
ABT's Days Sales Outstanding is ranked lower than
52% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. ABT: 62.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.85  Med: 74.01 Max: 145.87
Current: 62.33
56.85
145.87
Days Payable 71.50
ABT's Days Payable is ranked higher than
59% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. ABT: 71.50 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 63.79 Max: 159.8
Current: 71.5
35.38
159.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.63
ABT's Dividend Yield % is ranked higher than
84% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 1.12 vs. ABT: 1.63 )
Ranked among companies with meaningful Dividend Yield % only.
ABT' s Dividend Yield % Range Over the Past 10 Years
Min: 1.41  Med: 4.48 Max: 7.9
Current: 1.63
1.41
7.9
Dividend Payout Ratio 2.37
ABT's Dividend Payout Ratio is ranked lower than
88% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 0.32 vs. ABT: 2.37 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.42  Med: 0.68 Max: 13.4
Current: 2.37
0.42
13.4
3-Year Dividend Growth Rate 6.40
ABT's 3-Year Dividend Growth Rate is ranked lower than
57% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 9.70 vs. ABT: 6.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -31.2  Med: 10.6 Max: 22.9
Current: 6.4
-31.2
22.9
Forward Dividend Yield % 1.66
ABT's Forward Dividend Yield % is ranked higher than
84% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. ABT: 1.66 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.39
ABT's 5-Year Yield-on-Cost % is ranked higher than
67% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. ABT: 1.39 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.18  Med: 3.75 Max: 6.61
Current: 1.39
1.18
6.61
3-Year Average Share Buyback Ratio -5.00
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. ABT: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5  Med: 0.4 Max: 2.2
Current: -5
-5
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.15
ABT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
62% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. ABT: 2.15 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.37  Med: 0.86 Max: 2.15
Current: 2.15
0.37
2.15
Price-to-Median-PS-Value 1.42
ABT's Price-to-Median-PS-Value is ranked lower than
75% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ABT: 1.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 0.58 Max: 2.08
Current: 1.42
0.35
2.08
Price-to-Peter-Lynch-Fair-Value 13.17
ABT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
100% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. ABT: 13.17 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.32 Max: 38.22
Current: 13.17
0.33
38.22
Earnings Yield (Greenblatt) % 2.51
ABT's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. ABT: 2.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1  Med: 4.1 Max: 19.8
Current: 2.51
-1
19.8
Forward Rate of Return (Yacktman) % 14.13
ABT's Forward Rate of Return (Yacktman) % is ranked higher than
66% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. ABT: 14.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -19.2  Med: 15.45 Max: 31.7
Current: 14.13
-19.2
31.7

More Statistics

Revenue (TTM) (Mil) $30,402.00
EPS (TTM) $ 0.50
Beta1.62
Volatility15.46%
52-Week Range $53.61 - 74.15
Shares Outstanding (Mil)1,754.32

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 30,910 33,225
EBIT (Mil $) 3,467 4,411
EBITDA (Mil $) 7,167 8,061
EPS ($) 1.35 1.81 3.68
EPS without NRI ($) 1.35 1.81 3.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.86%
Dividends per Share ($) 1.13 1.19

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}